What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “TR115 will be administered orally twice daily until documented disease progression, unacceptable toxicity, withdrawal of consent, death, or study discontinuation.”In the company’s words, NCT07639879 on ClinicalTrials.gov
- Tested for
- PTCL, NK T-Cell Lymphoma, Ovarian Clear Cell Carcinoma, Endometrial Cancer, Stomach Cancer Recurrent, Urinary Bladder Cancer
- Main trialPhase 3
- “This is a randomized, open-label, multicenter Phase III study evaluating the efficacy and safety of TR115, an EZH2 inhibitor, versus investigator's choice (chidamide, golidocitinib, mitoxantrone liposome, or gemcitabine) in patients with relapsed and/or refractory peripheral T/NK-cell lymphoma. Approximately 180 patients will be randomized in a 1:1 ratio. The primary endpoint is progression-free survival (PFS) assessed by an Independent Review Committee (IRC). The key secondary endpoint is overall survival (OS). The study is being conducted at approximately 40 to 60 centers across China.”In the company’s words, NCT07639879 on ClinicalTrials.gov
Other drugs for PTCL
- SugemalimabCStone · Phase 3
- DibotatugDren Bio · Phase 1/2
- GNC-038Sichuan Baili (Biokin, SystImmune) · Phase 1/2
- GolcadomideCelgene · Phase 1/2
- IMC-001ImmuneOncia Therapeutics Inc. · Phase 2
- CD30.CAR-TTessa Therapeutics · Phase 1
Coming up2
- 1 May 2028Phase 2 trial completes · ClinicalTrials.gov
- 30 Jul 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 30 Jul 2029 | TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma | |
| Phase 2Not yet recruiting | 1 May 2028 | TR115 in ARID1A-Mutated Advanced Solid Tumors | |
| Phase 1Unknown | 30 Jul 2025 | TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026